Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. (Nasdaq: ALT) is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapeutics and vaccines addressing critical public health and biodefense needs. Leveraging the unique properties of its proprietary platform technologies, Altimmune is adept at swiftly designing product candidates targeting a range of diseases, including respiratory conditions, chronic infections, and cancer.
Altimmune's advanced Densigen™ T-cell platform technology is specifically designed to guide the immune system's response against complex disease targets by focusing on multiple antigens simultaneously. Another key platform, RespirVec™, uses needle-free intranasal delivery for faster and broader immunity against pathogens compared to traditional vaccines.
The company is also heavily involved in addressing obesity and liver diseases through its innovative peptide therapeutics. The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist under development for obesity and non-alcoholic steatohepatitis (NASH). Pemvidutide has shown promising results in clinical trials, achieving significant weight loss and liver fat reduction. It has received Fast Track designation from the U.S. FDA for treating NASH, highlighting its potential to meet significant unmet medical needs.
Altimmune's pipeline also includes HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. However, the company has recently decided to cease further development on HepTcell based on Phase 2 trial findings.
Financially, Altimmune maintains a robust cash position, enabling it to advance its clinical programs. Recent financial results indicate a focused investment in research and development, ensuring continued progress in its pipeline.
Significant recent achievements include:
- Positive top-line results from the 48-week MOMENTUM Phase 2 obesity trial of pemvidutide.
- Ongoing Phase 2b IMPACT trial of pemvidutide in MASH with top-line results expected in Q1 2025.
- Strong financial position with substantial cash reserves to support ongoing and future research activities.
Altimmune is poised at the forefront of developing transformative therapies for serious health conditions, potentially delivering significant advancements in patient care.
Altimmune presented results from a Phase 2 MRI-based body composition sub-study of pemvidutide at the 60th Annual Meeting of the European Association for the Study of Diabetes. The study, involving 67 subjects from the MOMENTUM obesity trial, showed promising outcomes for pemvidutide, a novel GLP-1/glucagon dual receptor agonist:
1. Lean loss ratio of only 21.9%, indicating excellent preservation of lean mass.
2. Even better lean mass preservation in subjects aged 60+, with a lean loss ratio of 19.9%.
3. 25.6% reduction in visceral adipose tissue (VAT) at the 2.4mg dose, compared to 20.1% loss in subcutaneous adipose tissue.
These results suggest pemvidutide's potential in reducing fall and fracture risks, especially in older adults, while also lowering cardiovascular disease risk through VAT reduction.
Altimmune (Nasdaq: ALT) announced that data from its Phase 2 MRI-based body composition sub-study of pemvidutide in overweight and obese subjects will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid. Pemvidutide, a novel GLP-1/glucagon dual receptor agonist, is being developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH) treatment.
The presentation, titled 'Pemvidutide preserves lean body mass during weight loss in patients with overweight and obesity,' will be given by Dr. Sarah Browne on September 10, 2024. Pemvidutide has shown promising results in clinical trials, demonstrating significant weight loss, reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure. The FDA has granted Fast Track designation for pemvidutide in MASH treatment.
Altimmune (Nasdaq: ALT) announced Q2 2024 financial results and provided a business update. Key highlights include:
- Presentations at major medical meetings supporting pemvidutide's differentiated profile in obesity and MASH
- Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH, with topline data expected in Q1 2025
- Cash position of $164.9 million as of June 30, 2024
- Data presented at ADA showing up to 15.6% weight loss at 48 weeks and class-leading lean mass preservation
- End-of-Phase 2 meeting with FDA expected in late Q3 2024
- Net loss of $24.6 million for Q2 2024, compared to $16.1 million in Q2 2023
Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has announced it will release its second quarter 2024 financial results on August 8, 2024. The company will also provide a business update during a conference call scheduled for 8:30 am E.T. on the same day. Investors can access the webcast live on Altimmune's Investor Relations website. Those wishing to join the call can register to receive dial-in numbers and a unique PIN. A replay of the call will be available on the Investor Relations website for up to three months after the event.
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat content (LFC)
- Up to 55.6% of subjects achieved LFC normalization
- Significant improvements in body weight and liver inflammation markers
- 94.4% of subjects achieved ≥30% relative reduction in LFC
- Well-tolerated with 2.9% adverse event discontinuations
Pemvidutide is currently in a Phase 2b IMPACT trial for metabolic dysfunction-associated steatohepatitis (MASH), with results expected in Q1 2025.
Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced its participation in the Leerink Partners Therapeutics Forum on July 9 and 10, 2024, in Boston, MA. The company's management team will engage in one-on-one meetings with institutional investors. This forum will include panel discussions with leading physicians focusing on autoimmune and metabolic diseases. Altimmune aims to leverage these interactions to advance its strategic objectives and investor relations.
Altimmune (Nasdaq: ALT) announced the unexpected passing of their Chief Financial Officer, Richard Eisenstadt, on June 24, 2024. President and CEO Vipin K. Garg expressed deep sorrow on behalf of the company, highlighting Eisenstadt's leadership and personal qualities. While the search for his replacement is underway, the finance and accounting team will manage his responsibilities.
Altimmune presented data from its 48-week Phase 2 MOMENTUM trial of pemvidutide at the ADA’s 84th Scientific Sessions. The trial focused on pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity treatment. Key findings show that 78.1% of weight loss was due to fat reduction, with only 21.9% from lean mass. The trial involved 391 subjects, achieving mean weight losses of 10.3%, 11.2%, 15.6%, and 2.2% for the 1.2 mg, 1.8 mg, 2.4 mg doses, and placebo, respectively. Additionally, pemvidutide improved serum lipids and blood pressure without notable cardiac events. These findings suggest that pemvidutide may offer a promising, long-term treatment for obesity.
Altimmune, a clinical-stage biopharmaceutical company, presented data on its GLP-1/glucagon dual receptor agonist candidate, pemvidutide, at the American Diabetes Association’s 84th Annual Scientific Sessions. Pemvidutide showed significant reductions in pro-inflammatory serum lipids, including total cholesterol, LDL-C, and triglycerides, by 28%, 26%, and 38% respectively. These lipid reductions were not linked to weight loss, implying a direct impact on lipid metabolism. The Phase 1 study involved 34 subjects receiving varying doses of pemvidutide or placebo for 12 weeks. Additionally, reductions in GlycA and GlycB, markers of systemic inflammation, and decreases in systolic and diastolic blood pressure were noted, suggesting a potential lowered cardiovascular disease risk.
Altimmune, a clinical-stage biopharmaceutical company listed on Nasdaq under the symbol ALT, will participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day on June 26, 2024. Company leaders, including CEO Vipin Garg, Ph.D., and Chief Scientific Officer Scott Roberts, Ph.D., will discuss insights from the American Diabetes Association's Scientific Sessions during a fireside chat at 9:30 a.m. EDT. The session will be webcast and accessible via the Events section of the Altimmune website.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
What does Altimmune, Inc. specialize in?
What are the main products in Altimmune's pipeline?
What is pemvidutide?
Has pemvidutide received any regulatory designations?
What is Densigen™ platform technology?
How does the RespirVec™ platform work?
What recent financial results has Altimmune reported?
What are the current clinical trials for pemvidutide?
What is the status of HepTcell™ development?
Where can I find more information about Altimmune?
